Autoimmune hepatitis (AIH) was the first liver disease for which an effective therapeutic intervention, corticosteroid treatment, was convincingly demonstrated in controlled clinical trials. However, 50 years later AIH still remains a major diagnostic and therapeutic challenge. There are two major reasons for this apparent contradiction: Firstly, AIH is a relatively rare disease. Secondly, AIH is a very heterogeneous disease.
The aim of the present Clinical Practice Guideline (CPG) is to provide guidance to hepatologists and general physicians in the diagnosis and treatment of AIH in order to improve care for affected patients.